Patient and treatment characteristics of the three treatment groups
| Alternative donor | High risk | Standard risk | |
| No of patients | 39 | 49 | 53 |
| Mean age (range) | 31 (14–48) | 41 (15–56) | 36 (16–56) |
| Sex: | |||
| Male | 23 | 27 | 32 |
| Female | 16 | 20 | 20 |
| Primary diagnosis: | |||
| ALL | 8 | 6 | 17 |
| AML | 10 | 17 | 20 |
| MDS/MPS | 7 | 10 | 0 |
| CML | 9 | 14 | 13 |
| Aplastic anaemia | 5 | 2 | 3 |
| GVHD Prophylaxis | |||
| T cell depletion + CyA | 37 | 37 | 50 |
| MTX + CyA | 3 | 10 | 6 |
| T cell depletion | 2 | 1 | |
| CyA | 1 | ||
| Conditioning: | |||
| Cyclo-TBI | 4 | 8 | 35 |
| Cyclo-TBI + Ara-C | 22 | 21 | 17 |
| Cyclo-TBI + VP-16 | 10 | 12 | 0 |
| Cyclo, busulphan | 3 | 8 | 1 |
| ATG | 31 | 0 | 0 |
ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; CML=chronic myeloid leukaemia; MDS/MPS=myelodysplastic−/myeloproliferative syndrome; BM=bone marrow; GVHD: graft versus host disease; MTX=methotrexate; CyA=cyclosporine A; Cyclo=cyclophosphamide; ATG=conditioning regimen also included antithymocyte globulins; TBI=total body irradiation.